Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 CAR-T with Concurrent BTK Inhibitor in B-Cell Lymphoma
NCT05020392Phase 3Unknown
- Start
- Sep 2021
- Primary completion
- Oct 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 3, open-label trial of ibrutinib, zanubrutinib and orelabrutinib in diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), follicular lymphoma (FL) and 2 more (2 arms). Primary endpoint: Incidence of Treatment-related Adverse Events at 2 years. Status: unknown.
02
Drugs
ibrutinibzanubrutiniborelabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Burkitt lymphoma (BL)follicular lymphoma (FL)chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05020392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05020392.